Add Yahoo as a preferred source to see more of our stories on Google. Oct. 31—(StatePoint) November is Pulmonary Hypertension Awareness Month, and the American Lung Association, with support from ...

Merck (NYSE:MRK) is approaching phase 2 data for Winrevair in pulmonary hypertension. Results will focus on the 6 minute walk ...

BACKGROUND: Right ventricular failure drives both morbidity and mortality in pulmonary arterial hypertension (PAH), but the mechanism of transition from compensated right ventricle (cRV) to ...

Panelists discuss how riociguat targets the nitric oxide pathway and is approved for both Group 1 PAH and Group 4 chronic thromboembolic pulmonary hypertension, with specific patient selection ...

Credit: Merck. Winrevair is a first-in-class recombinant activin receptor type IIA-Fc fusion protein designed to bind to activin A and other TGF-β superfamily ligands. The Food and Drug Administration ...

Pulmonary hypertension is traditionally defined as a mean pulmonary artery pressure of ≥25 mmHg when a patient is at rest, though a mean pressure of >20 mm Hg is considered to be abnormal and may ...

Pulmonary hypertension is a serious condition that happens when the blood pressure in the arteries of the lungs is higher ...

GSK PLC (LSE:GSK, NYSE:GSK) has agreed to acquire Canadian biotech 35Pharma for $950 million in cash, securing a ...

This transcript has been edited for clarity. Vallerie McLaughlin, MD: Hello and welcome to this Medscape InDiscussion on pulmonary arterial hypertension (PAH). Our topic today is the very important ...

Panelists discuss how managing patients with comorbidities requires careful evaluation to distinguish true Group 1 PAH features from underlying cardiac or pulmonary disease, with a more measured ...